Search

BioVentures Institute Sp. z o.o. received funding from the European Union (EU)

BioVentures Institute Sp. z o.o. received funding from the European Union (EU) via the National Centre for Research and Development (NCBiR) in cooperation with the Molecular Biotechnology Department, Faculty of Chemistry and Molecular Biology Department, Faculty of Biology, University of Gdansk, in the amount of 3 209 930 PLN (POIG.01.04.00-22-140/12) for the development of novel, recombinant DNA-based technology for generating artificial, hyper immunogenic antigens/vaccines, entitled: „A new technology of producing preventive and therapeutic vaccines for multiple stimulation of the human immune system”. The technology is universal, thus can be applied to most antigens, however, our first targets are HIV, HCV and HBV viruses.

Recent Posts

See All

Patent for EU

Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and environmental processes has been granted with European Union p